Non-Muscle Invasive Bladder Carcinoma — Trials

Non-Muscle Invasive Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 55
Recruiting: 35
Ph III recruiting: 8
Growth YoY: —
Industry share: 36%
Top sponsor: Janssen Research & Development, LLC
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04730232	Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable	unknown	Phase 2	63	Tianjin Medical University Second HospitalOTHER	1	Oct 29, 2021	clinicaltrials
NCT00816075	Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection	unknown	Phase 2 / Phase 3	40	Bozyaka Training and Research HospitalOTHER	1	Feb 17, 2009